Publikation:

A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine

Vorschaubild

Dateien

Plummer_2-jeem2dl5qfnv3.pdf
Plummer_2-jeem2dl5qfnv3.pdfGröße: 4.59 MBDownloads: 429

Datum

2019

Autor:innen

Plummer, Simon
Wallace, Stephanie
Ball, Graeme
Lloyd, Roslyn
Schiapparelli, Paula
Quiñones-Hinojosa, Alfredo
Pamies, David

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

URI (zitierfähiger Link)
http://nbn-resolving.de/urn:nbn:de:bsz:352-2-jeem2dl5qfnv3
DOI (zitierfähiger Link)
https://doi.org/10.1038/s41598-018-38130-0
ArXiv-ID

Internationale Patentnummer

Link zur Lizenz

CC BY 4.0

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Open Access Gold

Sammlungen

Biologie: Publikationen
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Scientific Reports. 2019, 9(1), 1407. eISSN 2045-2322. Available under: doi: 10.1038/s41598-018-38130-0

Zusammenfassung

A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690PLUMMER, Simon, Stephanie WALLACE, Graeme BALL, Roslyn LLOYD, Paula SCHIAPPARELLI, Alfredo QUIÑONES-HINOJOSA, Thomas HARTUNG, David PAMIES, 2019. A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. In: Scientific Reports. 2019, 9(1), 1407. eISSN 2045-2322. Available under: doi: 10.1038/s41598-018-38130-0
BibTex
@article{Plummer2019-02-05Human-45642,
  year={2019},
  doi={10.1038/s41598-018-38130-0},
  title={A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine},
  number={1},
  volume={9},
  journal={Scientific Reports},
  author={Plummer, Simon and Wallace, Stephanie and Ball, Graeme and Lloyd, Roslyn and Schiapparelli, Paula and Quiñones-Hinojosa, Alfredo and Hartung, Thomas and Pamies, David},
  note={Article Number: 1407}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/45642">
    <dc:language>eng</dc:language>
    <dc:creator>Schiapparelli, Paula</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Pamies, David</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-04-15T14:10:00Z</dc:date>
    <dc:creator>Ball, Graeme</dc:creator>
    <dc:contributor>Schiapparelli, Paula</dc:contributor>
    <dc:contributor>Lloyd, Roslyn</dc:contributor>
    <dc:contributor>Plummer, Simon</dc:contributor>
    <dc:contributor>Hartung, Thomas</dc:contributor>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/45642/1/Plummer_2-jeem2dl5qfnv3.pdf"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Wallace, Stephanie</dc:creator>
    <dc:creator>Plummer, Simon</dc:creator>
    <dc:contributor>Pamies, David</dc:contributor>
    <dc:creator>Quiñones-Hinojosa, Alfredo</dc:creator>
    <dcterms:title>A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine</dcterms:title>
    <dc:creator>Lloyd, Roslyn</dc:creator>
    <dc:contributor>Quiñones-Hinojosa, Alfredo</dc:contributor>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/45642/1/Plummer_2-jeem2dl5qfnv3.pdf"/>
    <dc:contributor>Wallace, Stephanie</dc:contributor>
    <dcterms:abstract xml:lang="eng">A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P &lt; 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.</dcterms:abstract>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Hartung, Thomas</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Ball, Graeme</dc:contributor>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/45642"/>
    <dcterms:issued>2019-02-05</dcterms:issued>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-04-15T14:10:00Z</dcterms:available>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen